Altimmune (ALT) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free ALT Stock Alerts $7.51 +0.49 (+6.98%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 1:44 PM | marketbeat.comAltimmune (NASDAQ:ALT) Shares Up 4.6%Altimmune (NASDAQ:ALT) Shares Up 4.6%May 30 at 4:50 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTMay 30 at 3:30 PM | prnewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitMay 30 at 5:45 AM | prnewswire.comShareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMay 29 at 4:19 PM | prnewswire.comROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 29 at 4:07 PM | seekingalpha.comAltimmune: Going All-In On PemvidutideMay 29 at 7:31 AM | globenewswire.comAltimmune to Participate at Two Upcoming Investor ConferencesMay 29 at 7:30 AM | globenewswire.comAltimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024May 29 at 5:45 AM | prnewswire.comThe Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming DeadlineMay 28, 2024 | seekingalpha.comAltimmune's Pemvidutide Is Not To Be DismissedMay 27, 2024 | investorplace.comThe Penny Stock Prophecy: 3 Overlooked Stocks Primed to PopMay 27, 2024 | stockhouse.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 27, 2024 | seekingalpha.comAltimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive ReturnsMay 26, 2024 | theglobeandmail.comROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 25, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 23, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 23, 2024 | prnewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitMay 23, 2024 | prnewswire.comAltimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALTMay 22, 2024 | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTMay 21, 2024 | markets.businessinsider.comBuy Rating Justified by Altimmune’s Promising Pemvidutide Efficacy in NASH TreatmentMay 21, 2024 | businesswire.comALT INVESTOR NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALTMay 21, 2024 | theglobeandmail.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 21, 2024 | prnewswire.comThe Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALTMay 20, 2024 | prnewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitMay 20, 2024 | businesswire.comRobbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their RightsMay 18, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneMay 18, 2024 | theglobeandmail.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 18, 2024 | fool.com3 Monster Stocks in the Making You Can Buy Right NowMay 17, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 16, 2024 | prnewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitMay 16, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Gap Up to $8.87Altimmune (NASDAQ:ALT) Shares Gap Up to $8.87May 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTMay 16, 2024 | marketbeat.comHC Wainwright Analysts Raise Earnings Estimates for Altimmune, Inc. (NASDAQ:ALT)Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright raised their Q2 2024 earnings per share (EPS) estimates for Altimmune in a research note issued to investors on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share oMay 15, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 15, 2024 | theglobeandmail.comROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 15, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Up 7%Altimmune (NASDAQ:ALT) Trading Up 7%May 15, 2024 | theglobeandmail.comROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)May 15, 2024 | marketbeat.comShort Interest in Altimmune, Inc. (NASDAQ:ALT) Expands By 9.5%Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 22,310,000 shares, an increase of 9.5% from the April 15th total of 20,370,000 shares. Based on an average daily trading volume, of 4,570,000 shares, the days-to-cover ratio is presently 4.9 days.May 15, 2024 | prnewswire.comAltimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALTMay 14, 2024 | markets.businessinsider.comBuy Rating Justified: Altimmune’s Pemvidutide Shows Best-in-Class Potential for Obesity and MASHMay 14, 2024 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)May 14, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research note on Tuesday.May 14, 2024 | prnewswire.comContact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)May 14, 2024 | prnewswire.comALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 13, 2024 | prnewswire.comALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMay 11, 2024 | markets.businessinsider.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTMay 11, 2024 | finance.yahoo.comAltimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Altimmune on Pemvidutide’s Potential and Strategic Advancements Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” ALT Media Mentions By Week ALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.360.79▲Average Medical News Sentiment ALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼155▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Y-mAbs Therapeutics News COMPASS Pathways News SIGA Technologies News Olema Pharmaceuticals News Aerovate Therapeutics News Heron Therapeutics News Entrada Therapeutics News Avid Bioservices News Harrow News Astria Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
